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Targeted therapy including anti-angiogenic therapy,
kinase inhibitors, and immunotherapy dominate cancer
drug development in renal cell carcinoma (RCC) and
malignant melanoma (MM), where traditional meth-
odologies have failed. Myeloid-derived suppressor cells
(MDSC) may represent a mode of resistance to such
treatments and require investigation in human patients.
Here we explore the relationship between conventional
neutrophils and neutrophilic-MDSC (nMDSC) in RCC
and MM. We show that T-cell suppressive nMDSC con-
sist of hypodense CD11b+CD15+CD14- immature
CD16- myelocytes/metamyelocytes and mature CD16+
neutrophils co-precipitating with peripheral blood
mononuclear cells (PBMCs) in patient blood (n=22) and
tumors (n=16). Such cells were not significantly present
in healthy blood donors (n=5). In parallel, conventional
neutrophils co-precipitating with red blood cells (RBCs)
were found to be uniquely immunosuppressive when
isolated from RCC or MM patients (n=8), but not when
isolated from healthy blood donors (n=5)(p<0.05). Both
hypodense n-MDSC as well as conventional neutrophils
from cancer patients expressed increased levels of pro-
angiogenic molecules (n=4) and enhanced tumor-
associated angiogenesis of RCC and MM xenografts in
nude mice (p<.0001). This functional shift in mature
neutrophils was modeled in vitro upon exposure of
healthy donor derived neutrophils to tumor cell condi-
tioned medium; and, was associated with an increase in
neutrophil production of immunosuppressive arginase and
reactive oxygen species, as well as an increase in proangio-
genic molecule expression and in vivo angiogenic activity
(n=3, p<.0001). The data support a role for nMDSC that
are both T-cell suppressive and pro-angiogenic in RCC
and MM cancer patients. Furthermore, our experiments
suggest that n-MDSC arise via the parallel premature
egress of bone marrow myeloid precursors as well as a
functional switch in conventional neutrophil activity in
cancer patients. Such activity is at least in part mediated
via soluble tumor-derived factors which may circulate in
patient blood. Ancillary strategies targeting myeloid cells
may be an important part of future clinical trials to
enhance the potency of targeted therapy.
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